Understanding, creating, and working with formulary systems

American Journal of Managed Care

Volumn 5, Issue 10, 1999, Pages 1311-1319

  Quinn, Campion E ^a,c   Barisano, Anthony ^b  

^a Campion Quinn and Associates   (United States)

^b Vytra Health Care   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PROTOCOL; DRUG CHOICE; DRUG FORMULARY; HEALTH MAINTENANCE ORGANIZATION; MEDICAL DECISION MAKING; PHARMACY; PRIORITY JOURNAL; REVIEW;

DECISION MAKING; DRUG COSTS; EDUCATION, MEDICAL, CONTINUING; FORMULARIES; HUMANS; MANAGED CARE PROGRAMS; PHARMACY AND THERAPEUTICS COMMITTEE; UNITED STATES;

EID: 0032704051     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Highlights of the National Health Expenditure Projections, 1997-2007. Rockville, MD: Health Care Financing Administration; 1998.
2. Tanouye E. US develops expensive habit with drug sector growth spurt. The Wall Street Journal, November 16, 1998:A1.
3. Academy of Managed Care Pharmacy. Concepts in Managed Care Pharmacy Series: Formulary Management. Available at: http://www.amcp.org/public/pubs/concepts/form_man.html. Accessed September 1, 1999.
4. Navarro R, Wertheimer A, eds. Managing the Pharmacy Benefit. Warren, NJ: Emron Publishing, Inc; 1996:109.
5. Thomas N, Larson L, Bell N. Pharmacy Benefits Management. Brookfield, WI: International Foundation of Employee Benefit Plans, Inc; 1996:53.
6. Shea BF, Churchill WW, Powel SH, et al. P&T committee overview: Brigham and Women's Hospital. Pharm Pract Manag Q 1998;17(4):76-83.
7. Heemink I, Merlero-Montes M, Tabit E, et al. Review of the functioning of P&T committees in Boston area hospitals, part 1. Pharmacol Ther May 1999:218-237.
8. Manasse HR. Medication use in an imperfect world: Drug misadventuring as an issue of public policy, part 1. Am J Hosp Pharm 1989;46:929-944.
9. Johnson JA, Bootman JL. Drug-related morbidity and mortality: Cost of illness model. Arch Intern Med 1995;155:1949-1956.
10. McKenny JM, Harrison WL. Drug-related hospital admissions. Am J Hosp Pharm 1976;33:972-995.
11. Weekes LM, Day RO. Drug Saf 1998;18(3):153-159.
12. Lyles A, Luce BR, Rentz AM. Managed care pharmacy, socioeconomic assessments, and drug adoption decisions. Soc Sci Med 1997;45:511-552.
13. Kessler JM. Decision analysis in the formulary process. Am J Health Syst Pharm 1997;54(suppl 1):S5-S8.
14. Goodman S. Toward evidence-based medical statistics, part 1 : The P value fallacy. Ann Intern Med 1999;130:995-1004.
15. Langley P, Sullivan S. Pharmacoeconomic evaluations: Guidelines for drug purchasers. J Manag Care Pharmacy 1996;2(6):671-677.
16. Hillman A, Pauly M, Escarce J, et al. Financial incentives and drug spending in managed care. Health Aff 1999;18(2):189-200.
17. Novartis Pharmacy Benefit Report: Facts and Figures. Warren, NJ: Emron Publishing Inc.; 1997.
18. Gross DJ. Prescription drug formularies in managed care: Concerns for the elderly population. Clin Ther 1998;20:1277-1291.
19. Rauber C. Drug wars: Health care plans blast California regulators for requiring them to retain medications on their formularies. Modern Health Care, May 10, 1999:74.